Who is sponsoring NCT03354754?

NCT03354754 is sponsored by Novartis Pharmaceuticals.

What condition does NCT03354754 study?

NCT03354754 studies Intra-abdominal Infections.

What drugs are being tested in NCT03354754?

Interventions: LYS228, Standard of care therapy.

What is the status of NCT03354754?

NCT03354754 is currently TERMINATED.

Last reviewed 2021-10-11 · How we verify

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

NCT03354754 PHASE2 TERMINATED Results posted

The purpose of the study was to evaluate whether LYS228 can be developed for the treatment of complicated intra-abdominal infections. It was planned that LYS228 exposure across patients with varying renal function would be evaluated during the study to confirm that LYS228 concentrations are predicted to be adequate to treat the patient population. It was planned that the PK exposure of the initial 8 patients would be analyzed. PK analysis was not conducted as per protocol the first analysis required 8 patients.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE2
Status	TERMINATED
Enrolment	3
Start date	Tue May 15 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Sep 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Intra-abdominal Infections

Interventions

LYS228
Standard of care therapy

Countries

United States